
Scientists in the US have reported findings suggesting that certain molecules in the blood are strongly associated with complications during …

Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million …

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

Topas Therapeutics, a German company focused on developing novel therapeutics to treat immune-mediated and autoimmune diseases, announced that it has …

In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the …

A group of states, 45 members-strong, has expanded its probe into the generics pharmaceutical industry by expanding its case to …

AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab …

Figures released by NHS Scotland have revealed that the numbers of deaths from cancer are 67% higher in the poorest …

Shire has revealed that it plans to sell one of its manufacturing sites in Milford, Massachusetts, having already entered active …

Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would …

Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …

AstraZeneca has agreed to license AZD9668, its experimental drug for the treatment of alpha-1 antitrypsin deficiency, to Mereo Biopharma for …

Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce …

Samsung Biologics has announced it has expanded its strategic alliance with MSD, or Merck as it is known in the …

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …